 SOUTH SAN FRANCISCO, Calif., Jan. 17, 2023 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM products for cancer, today announced that it will participate in two upcoming investor conferences. 